Research & Innovation

The FDA has approved Korsuva (difelikefalin) for moderate to severe pruritus associated with chronic kidney disease.

Our Global Medical Office has created an interdisciplinary critical care team to help develop new critical care delivery improvements.

While global COVID-19 data confirms that dialysis patients experienced a high rate of hospitalization and death, there has been insufficient research into many issues surrounding individuals with end stage kidney disease.

While current COVID-19 vaccines are very effective, manufacturers are developing strategies to ensure that new vaccines can keep pace with the rapid rate of mutation.

Our connected health platforms empower patients and clinical staff through a digital ecosystem that connects patients with healthcare professionals, medical devices, and customer service.

We are driving innovation and transformation in kidney care with research into regenerative medicine, organ transplant, and organ recovery.

The Centers for Medicare and Medicaid Services (CMS) established the ESRD Prospective Payment System (PPS) to facilitate beneficiary access to renal dialysis equipment.

Our Global Medical Office has started a program to understand regional factors affecting performance in improving care for people with end stage kidney disease.

We are devoted to providing precise and personalized care, while improving vascular access for people on hemodialysis.

Patients who are active partners in their care report better physiological and psychological outcomes compared to those in more traditional dialysis care settings.

As several different COVID-19 vaccines are authorized for emergency use and/or approved around the world, the race to contain the pandemic has been given a new weapon.

Learn how we took the lead in developing strategies to protect patients, families, caregivers, and clinical staff from COVID-19.